# Comprehensive multi-omics analysis of tandem duplicator phenotypes in non-small cell lung cancer

## TL;DR

This study explores how genomic tandem duplications in lung cancer affect patient outcomes and treatment responses.

## Contribution

The study introduces a classification strategy for TDP based on span size, linking it to chemotherapy sensitivity and prognosis.

## Key findings

- Smaller span size TDP is associated with genome complexity, immune activity, and better prognosis.
- Larger span size TDP correlates with opposite trends, including lower drug sensitivity and poorer outcomes.
- TDP classification can help predict chemotherapy response in non-small cell lung cancer patients.

## Abstract

The Tandem Duplicator Phenotype (TDP) is a prominent genomic metric prevalent in non-small cell lung cancer (NSCLC).

Multi-omics samples including DNA copy number, transcriptomics, somatic single-nucleotide variations, clinical data, and cell-line drug sensitivity from TCGA and CCLE are delved into TDP characteristics.

Our thorough analysis reveals that patients with smaller span sizes TDP have a more intricate genome, moderate pathology, enhanced therapeutic response, favorable prognosis, a more active immune system, and higher drug sensitivity. In contrast, those with larger span sizes TDP exhibited opposite trends.

The integrated analysis underscores that an in-depth molecular assessment of TDP can offer invaluable insights into its role in cancers. Classification strategy of TDP could recognize the chemotherapy sensitivity of different NSCLC patients.